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Summary.-A recent international survey on the size of clinical trials in cancer
showed the frequent problem of slow patient accrual, which remains a major hin-
drance to progress.
The survey also revealed that, although the design of most trials specified a fixed
number of patients, subsequent experience revealed a much more flexible approach,
with analysis of results, say, every 4-6 months. Conventional sequential methods
are hardly ever used and unfortunately most trials proceed without any predeter-
mined stopping rules.
Some trial organizers use repeated significance tests on accumulating data as a
guide to the detection of treatment differences, an approach that can be adapted to a
more rigorous statistical framework as a "group sequential design". The major
statistical principle involved is that the more often one analyses the data the greater
is the probability of achieving a statistically significant result, even when the two
treatments are equally effective.
Group sequential designs require the adoption of a more stringent significance
level to allow for repeated testing. If one intends up to 10 repeated analyses of the
data, only a treatment difference significant at the 1% level would merit a decision
to stop the trial.
For any trial to implement a stopping rule successfully there must also be prompt
feedback and processing of response and survival data ready for up-to-date analysis.
Such efficiency is often lacking.
The repeated presentation of interim results of a trial to participating investi-
gators can seriously affect their future reaction, especially if there are interesting
but non-significant differences. Thus, some secrecy about ongoing results is advis-
able if trials are to achieve an unbiased conclusion.
IN THE EXECUTION of any clinical trial
for the treatment of cancer it is gener-
ally considered unethical and also very
inefficient to wait until the results on all
patients have been obtainedbefore making
any inferences about the effectiveness of
treatments. In statistical parlance the
"fixed sample size" approach is unaccept-
able. Nevertheless many trial protocols
specify a fixed number of patients, often
with certain statistical design objectives in
mind, but one assumes from experience
thatthe trial organizers do not intend to be
as inflexible as they imply.
At the other extreme there exist
methods ofsequential design and analysis,
as described in Armitage (1975), which
are geared to the idea that after every
additional patient on each treatment has
been evaluated, some formal statistical
stopping rules are applied to determine
whether the whole trial should stop. Such
a sequential approach is likely to involve
certain assumptions:
(1) the response variable conforms to
some standard statistical distribution,
(2) patients enter in matched pairs (one
to each treatment);
(3) patient evaluation is instantaneous;
(4) constant surveillance is made of
the accumulating data.
The situation for a typical cancer
clinical trial is rather different:
(1) response is measured either byS. J. POCO K
tumour shrinkage, disease-free interval or
patient survival, any of which may have
awkward distributions;
(2) patients vary with respect to
several prognostic factors, and although
stratification can be a partial solution,
pairing of patients is impractical;
(3) responses such as those mentioned
in (1) may take months or years to
observe; moreover, patient entry from
several hospitals will require a com-
plex system of central data collection
which entails some delay between patient
evaluation at the hospital and inclusion
of his outcome in the analysis;
(4) the statistician and trial organizers
will normally be too busy to maintain a
constant vigil over the data in order to
observe the point at which a sequential
boundary is crossed.
Hence there is a sharp contrast between
the theoretical ideal ofsequential methods
and the practical situation of cancer
clinical trials. This is certainly my own
experience, since I am unaware of any
cancer clinical trial which has success-
fully implemented a formal sequential
design.
Therefore neither fixed sample size nor
conventional sequential methods are
applicable. Instead the cancer clinical
trial will normally proceed with some
inspection of results from time to time
with an informal interpretation by the
trial organizers as to whether any action
to stop or change a treatment is justified.
Some fixed sample-size significance tests
may be used to aid decision making, but
the overall approach is subjective. One
might take the defeatist standpoint that
any more formalized approach to the
design and analysis of trials is unrealistic.
However, I think this is liable to result in
a very unscientific approach to clinical
trials, whereby the statistical validity of
conclusions would remain uncertain.
What is needed is a method ofstatistical
design and analysis which takes into
account the fact that it is common
practice to assess the accumulating results
of an ongoing trial at several equally
spaced times, eachofwhichmightnormally
occur before a meeting of the trial
organizers. This paper describes one such
general type of group sequential design
based on the repeated use of conventional
significance testing.
However, before we go into the details
of such an approach, we should consider
the current status of clinical trial practice.
A SURVEY ON THE SIZE OF CANCER TRIALS
This survey was undertaken for the
UICC Project on Controlled Therapeutic
Trials by Pocock et al. (1978). The main
questions of the survey were:
(1) Do investigators determine the
required size of trial in advance?
(2) How successful are they in accruing
an adequate number of patients?
(3) Do they assess interim results while
thetrialisinprogress, and do such analyses
affect the eventual size of trial?
The sampling frame for the survey was
the 334 trials registered with the UIJC
information office from 1972 to mid-1975.
A random sample of 50 trials was chosen,
and a questionnaire sent to each principal
investigator. Completed questionnaires
were received from 40 (80%). Eighteen of
these were in Western Europe, 17 in the
United States and 5 elsewhere. Twenty-
eight of the trials accrued patients from
more than one centre, and 17 ofthese had
more than 20 participating centres. All
trials were randomized, this being a
condition for inclusion in the UICC
register. Twenty-eight of the trials had
just 2 randomized treatment groups.
Twenty-six trials were for chemotherapy,
which is probably a true reflection of
current trial activity. The trials covered
a wide range of tumour sites, including 9
for leukaemia.
The replies to the most relevant
questions are presented in 3 sections:
(a) Design
In 34/40 cases (85%) the required
number of patients was specified before
the trial began. The actual number was
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recorded in 26 cases and the d
was as follows:
9 trials required 45-90 patie
12 100-200
1 210
1
2
1
400+
500
1690
The methods ofdeterminingt
sample size were as follows:
18 used power calculations I
number of patients;
8 made a subjective decisic
statistical methods;
1 used a sequential design,
abandoned later;
3 made somewhat unusual
statements; and
4 used statistical methods
details given.
Thus, statistical power calcu
determining a fixed size of tria]
most popular approach. This
(1) making a decision as to
smallest difference in treatmi
which it is important to detect
(2) defining a single signifi
and level (say P < 0.05) to be
only at the end ofthe trial as t:
for detecting that a difference e
(3) specifying a degree of
(say 90%) that the detection X
for the underlying difference (1
successful. Therequirednumber
can thence be obtained from
statistical formula.
This method can give rise
wide range of sample size neec
trated in this survey. The 169
required in one trial reflects a st;
excessive adherence to this
without consideration of wh
feasible rate of accruing patieni
realistic approach is normally
whereby the power calculations
to fit a preliminary subjectiv
on how long a trial should las
availability of suitable patients.
listribution statistical methods are used as a check on
the scientific acceptability of a choice
1ts (all already made on practical grounds. This
treatments seems reasonable provided the statistical
comatbined) statements (1)-(3)abovedo notbecome too combined) optimistic. Unfortunately, in 8 of the
above trials a 100% difference in median
survivalormediandisease-freeintervalwas
used as the basis for power calculations,
sherequired which resulted in relatively small sample-
size requirements ofaround 30-50 patients
for a fixed per treatment. This enthusiasm ofinvesti-
gators for small Phase III trials in the
in, without hope of very large treatment differences is
a considerable hindrance to progress in
which was cancer research.
statistical (b) Realization
At the time of this survey only half of
with no the trials had terminated patient accrual,
so that one cannot give an overall picture
of their eventual outcome. However, since
ilations for all trials had been in progress for at
I seems the least 2 years one can study the mean
involves: annual accrual rates. This information
was available for 39 trials, and the what iScth distribution is as follows:
ent effects stbuon1asflw:
3 trials entered < 10 patients/annum
icance test 8 10-19
used once 6 20-29
ie criterion 8 30-49
exists; and 8 50-79
certainty 5 100-199
method (2) 1 266
) would be
ofpatients Another way of considering a trial's
a simple progress is to calculate the number of
years of patient accrual required to
to a very achieve the target number specified in the
Is, as illus- trial design. This information was avail-
0'patients able for 24 trials and the distribution is
atisticiants as follows:
approach, 3 trials require under 2 years
at was a 2 2-3 years
ts. A more 7 3-4 years
T adopted, 7 4-8 years
3 are made 5 10 years.
e decision
;t and the In summary, the median accrual rate
Thus, the is 33 patients per annum and the median
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time to achieve the specified accrual
target is over 4 years. Clearly, this is a
very unsatisfactory situation, w}hich re-
sults in many trials either failing to
achieve adequate patient numbers or
being excessively protracted. Further
study of the survey results indicates that
both single-institution and multicentre
trials experience these problems. Until all
trial organizers obtain a truly realistic
assessment of the potential patient ac-
crual, and ensure the full cooperation of
all contributing investigators, the problem
of poor accrual will continue to ruin a
large proportion of clinical trials.
(c) Analysis
Investigators were asked whether they
had undertaken any form of interina or
ongoing analysis of results while the trial
was in progress. 33/40 (83%) responded
Yes and the frequency of interim analysis
was as follows:
Every 3 months
Every 4 months
Every 6 months
Every vear
Every 2 years or less
Sequential analysis
One toxicity analysis only
Unknown
1
9
13
3
2
2
2
1
Evaluation of the trial every 4-6 months
seems a very common practice, which is
probably linked to the tri- or bi-annual
meetings ofthe trial organizers. One ofthe
two sequential analyses was eventually
abandoned, whilst the other involved a
separate sequential treatment comparison
within each of several patient strata with
reporting of results every 3 months, so
that neither remained truly sequential.
Six of the 7 who had not undertaken
interim analyses implied they would do
so once there was sufficient data.
Investigators were also asked whether
they used any formal or informal stopping
rules for the early termination of trial if
treatment differences should develop. The
38 replies were as follows:
22 had no stopping rules
2 used sequential methods, as men-
tioned earlier
6 used repeated significance testing
4 adopted a subjective approach based
on the magnitude oftreatment differ-
ence
I used a peculiar statistical argument
3 used some stopping rule, but gave
no details.
Thus the majority had no agreed policy
as to early termination of trial. This is
unfortunate since the whole object is to
identify a superior treatment and to en-
sure that patients will not receive an
inferior treatment once a difference is
clearly established.
Repeated significance testing means
that at periodic intervals, say every 6
months, one or more significance tests are
carried out to see whether there is evi-
dence of a treatment difference. If statis-
tical significance is reached at some point,
this will be used as the basis for a decision
to stop the trial. This approach seems
quite sensible in that, unlike many sequen-
tial designs, it is readily understood by
both statisticians and clinicians. How-
ever, there are 3 major problems which
need to be clarified:
(I) If there are several measures of a
patient's response to treatment, e.g.
tumour shrinkage, survival, toxicity,
disease-free interval, then it is quite
likely that some will show significant
differences and others will not. This
presents a logical problem which may be
overcome by giving primary importance to
onevariableandusingothercomparisons as
a more informal check that the superiority
of one treatment follows a consistent
pattern. Alternatively, one could define
some single more complex multivariate
significance test based on all relevant
variables, but this may be unrealistic in
the caseofsuchdisparatefactorsastumour
response and toxicity.
(2) One cannot expect clinical investi-
gators to accept a significance test as the
sole criterion for stopping a trial. Previous
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experience, evidence from trials in other
centres and the degree of enthusiasm for
the trial, will all necessarily be taken into
account. Thus the ultimate decision will
be a subjective one but it is important
that statistical evidence be a primary
factor.
(3) The more often one performs a sig-
nificance test on the accumulating results
in a trial, the greater is the chance that
some significant difference will eventu-
ally be detected, even ifthe treatments are
really equally effective. This fact will tend
to contribute to an excess of false positive
results reported in the clinical trial
literature. Hence repeated examination of
data means that one must set a more
stringent significance level than P < 0 05,
and this point is discussed further in
the next section. However, before we
approach this more statistical topic it
may be helpful to state the following
simple rule:
Ifone expects to take up a maximum of
I 0 repeated looks at one's data during the
course of a trial, then one might wish to
adopt a significance level of P < 0-01 as
the criterion for stopping the trial, since
the chances of drawing a false conclusion
that one treatment is superior is roughly
equivalent to making a decision based on
a single test at the level P < 0-0,5.
GROUP SEQUENTIAL ANALYSIS
This section describes how repeated
significance testing of accumulating
data can be formulated as a precise
method of statistical analysis for clinical
trials. Armitage (1975) describes several
RST sequential designs based on signifi-
cance testing after each pair of patients,
one to each treatment. However, as
mentioned in Section 1, this continual
testing has both theoretical and practical
difficulties. Instead we consider the group
sequential approach, whereby significance
tests are performed at longer equally
spaced intervals. The results and methods
described here are based on Pocock (1977)
and further reference to the same general
approach can be obtained from McPherson
(1974, 1977).
First, we return to the problem that
repeated significance tests increase the
overall significance level, that is, the
probability of at least one significant
difference when the treatments are really
the same. Table I shows the results for
TABLE I. Repeated significance tests on
accumulating data (two treatments and a
normal response variable)
No. of repeated signifi-
cance tests at the 500
level
I
2
4
5
10
20
50
100
1000
oo
Overall significance
level
O 05
0 *08
0-11
0-13
0-14
0-19
0 *25
0-32
0 37
0 *53
1
repeated two-sided testing at the 5%0
level at equally spaced numbers ofpatients
with two treatments, and a normally
distributed response variable with con-
stant known variance, though broadly
similar results hold for any type of re-
sponsevariableandanypattern ofrepeated
testing. For only 10 repeated tests the
overall significance level has increased
from 0405 to 0419, and with more and
more repeated testing one can become
increasingly sure of declaring a treatment
difference whether one is really present or
not. Clearly the naive application of
repeated significance testing allows the
unscrupulous investigator ample scope to
demonstrate some significant advance in
the treatment of cancer!
The way to correct for this problem is
to choose a more stringent nominal
signifi cance level for each repeated test,
so that the overall significance level is
0 05. Table II shows what these nominal
levels need to be for the case of a normal
response, though simulation has showni
that the same nominal levels are accurate
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TABLE II.-Nominal significance levels
corresponding to an overall significance
level of 0 05 (normal response)
No. of repeated signifi- Nominal significance
cance tests level
2 0 0294
3 0-0221
4 0-0182
5 0-0158
10 0 *0106
15 0 *0086
20 0 0075
for a wide variety of response variables.
Furthermore, these results hold for more
elaborate tests involving adjustment for
covariates, and are not sensitive to minor
variations away from exactly equal num-
bers of additional patients between tests.
This simple adjustment can thus make
repeated significance testing a respectable
statistical tool, the only restriction
being that one must decide in advance
how many repeated tests are to be per-
formed.
;p
Fi
Let us illustrate the approach with data
from an actual trial of two drug combina-
tions, CP (cytoxan-prednisone) and CVP
(cytoxan-vincristine-prednisone), for the
treatment of advanced non-Hodgkin's
lymphoma. The main criterion for res-
ponse was tumour shrinkage, and the
Figure shows how the response rates on
the two treatments varied over the course
of the trial, patient accrual being from
June 1972 to October 1974. It can be seen
that every time a patient is evaluated the
response rate changes and, as in the early
stages of any trial, this leads to wild
fluctuations. However, as patient numbers
increase, the curves inevitably become
more stable.
Now, suppose the intention was to have
around 120-130 patients in the trial and
to analyse the accumulating data on
5 occasions, i.e. after about every 25
patients. This would lead to analyses at
the times marked t in the Figure with
the following results:
CVP
atients
CP
tients
FIG. Cumulative response rates for treatments in a clinical trial for advanced non-Hodgkin's
lymphoma.
762
R
e
s
p
n0
s
e
R
a
t
eCANCER CLINICAL TRIALS
Response rates x2 (without
continuity
CP CVP correction)
January
1 97:3
July 197,3
November
1973
April 1974
October
1974
3/14
11/27
5/11 1-63
13/24 0 92
18/40 17/36 0 *04
18/54 24/48 3 25 {
23/67 :; I/,-)9 4 - 25{
p
>0 05
<0-1
>0-0158
<0*05
At each of the 5 times the response
rates are compared using a x2 test without
continuity correction, with the intention
of stopping the trial if P < 0O0158, the
nominal significance level obtained from
Table II. The lack of continuity correction
is necessary to avoid the repeated testing
being unduly conservative (see Pocock,
1977). Even with P < 005 on the final
test, one could not declare a treatment
difference significant at the 500 level,
since the nominal P value of 0O0158 was
not achieved. Of course, one would not
wish to take a totally negative interpreta-
tion for this trial. In practice one would
infer from this data alone that the
superiority of CVP with regard to tumour
response is interesting but inconclusive.
Eventually, further data on the duration
of response and patient survival would
help to clarify the situation.
Superficially, this exampleillustrates the
ease with which group sequential methods
can be used. In fact, there are several
difficulties that need to be raised. Tumour
response is not seen instantaneously,
and can take up to several weeks to be
seen. The simplest solution is to allow a
fixed period, say 3 months, to observe
whether response occurs in a patient. This
means that analysis after each group of
patients takes place 3 months later than
was indicated above, i.e. the first analysis
would have been made in April 1973, not
January 1973. Such an unavoidable delay
means that further patients will have
entered the trial in the interim, and this
may raise complications if the nominal
significance level is achieved and the
trial is stopped. If stopping the trial
51
means that all patients still receiving the
inferior treatment are taken off it instan-
taneously, there will be no further direct
data on response and the treatment
comparison remains unaltered. However, if
it is thought appropriate for patients
entered but not evaluated to completetheir
current therapy, there will be further res-
ponsedatawhichmayslightlyalterthefinal
treatment comparison. This can lead to
contradictions if the results become less
significant, but should not be a serious
problem unless the delay to observe re-
sponse is unduly long.
In this regard, there may be adminis-
trative delay in getting the observed
response reported for inclusion in analysis.
In multicentre cooperative groups this
can be a matter of months, in which case
any stopping rule becomes greatly delayed.
For instance, the above example illustrates
how one would have liked to conduct the
ongoing analysis of the trial, whereas in
practice the delays were such that the
final response data were not analysed until
over a year after the last patient was
entered. It seems to me that for the
benefit of patients participating in clinical
trials there must be a considerable im-
provement in the feedback and processing
of response data, in order that a prompt
analysis can be carried out and any
inferior treatment detected.
GROUP SEQUENTIAL DESIGNS
We now consider how the method of
repeated significance testing can be formu-
lated into the design of a clinical trial,
particularly as regards power calculations.
The two features to be decided on at
the start of such a group sequential
trial are:
(a) How many significance tests should
there be, i.e. what is the maximum
number of groups?
(b) How many patients should be
evaluated before each significance test,
i.e. what should be the size of each group?
Let us here consider a trial with two
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treatments, 2n patients per group (n per
treatment) and a maximum of N groups.
This makes the maximum size of trial
2nN.
The method of determining the opera-
ting characteristics of designs with a
variety of values for n and N is described
by Pocock (1977). Here we consider the
simplest theoretical case of two treatment
groups, for each of which we have a
normally distributed response with means
/LA, HLB and known variance a2. The
conventional power calculation here re-
quires specification of an overall signifi-
cance level ac and power 1 /3 for a
specific alternative hypothesis ILA M-B
8. Tables derived by numerical integration
enable the required value of n for any
given N to be determined, but for limita-
tions of space let us here just consider
results for cx 0-05 and 1 /3 0-9
presented in Table III. Remember that
the required nominal significance levels for
any choice of N are to be found in Table
II. Clearly, as the number of groups N
increases, the number per group 2n de-
creases and the maximum number of
patients 2ntN increases.
This means that the larger is N for a
given cx and /3, the longer the trial will
take to complete if the null hypothesis of
no treatment difference appears to be
true. Table Ill shows that in this situation
2000 more patients will be needed for
a design with N1 5 compared to a "one-
look" trial (N 1).
However, this is compensated by the
most important feature in a group sequen-
tial design, which is the extent to which it
enables early termination oftrial when the
alternative hypothesis is true. This is
indicated in the last column of Table III
by the average sample size. Evidently the
greatest reduction is achieved by using a
2-group design instead of a I-group
(i.e. fixed sample size) design and there
appears little advantage in using a design
with more than 5 groups. This applies to
any trial design based on a - 0 05 and
1 - /3 0-9, and similar examples could
be evaluated for other values of a and /3.
The only advantage of designs witlh a
large number of groups (i.e. repeated
significance tests) is in the early detection
of extremely large treatment differences.
Consider one extreme case of repeated
significance testing after every pair of
patients (i.e. an RST sequential design)
for of-0 0-05, 1 /3 0 9 and 8 = 0 5a.
The required maximum sample size is
242 and the average sample size under
HA is 116-6 compared with 115 2 for the
equivalent 5-group design. Thus, con-
tinual significance testing has no statis-
tical advantage compared with occasional
testing at 5 equally spaced intervals.
It has been suggested that the nominal
significance level could be varied over the
N tests, possibly having more stringent
tests early on in the trial, but it is
unclear what statistical advantage this
might have to compensatefortheincreased
complexity of design.
Of course, the response variable in a
TABLE III Group sequential designs for a nornal response with known variance a2.
overall significance level of 0-05 and power 1 /3 0 9 under HA: HLA - /[B S8
Required No. of
patients per
group
(2n)
42 04'
23-12
16-11
12 43 x
'-
10-14 1
2
5 351
2-79J
Maximum No.
of patients
(2tiN)
42 04
46-24j
48-33
49- 72 x a
J0 70
5:3 -50
55 -S 80J
Average No. of )atients
to termination of
trial undi(ler HA
42 041
32 60
30 29
29-33 x a2
28 80
28 03
27 -98J
Maximum
No. of grouips
(N)
]
2
3
4
5
10
20
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clinical trial rarely follows a normal
distribution, but for trials with relatively
few groups this is not a serious problem,
since asymptotic normal approximations
can be used with sufficient accuracv. In
particular, Pocock (1977) describes how
binary and exponential responses can be
used for group sequential designs. Also,
in most trials it is important to allow for
prognostic factors in making treatment
comparisons, but provided one does not
include too many factors, the inclusion of
covariate adjustment in analysis will
have no serious effect on the operating
characteristics ofgroup sequential designs.
SURVIVAL DATA
It is becoming widely accepted that
most survival data are best analysed
by non-parametric methods. Armitage
(1975) and Jones & Whitehead (in press)
have considered sequential analysis based
on the log-rank test. However, repeated
analysis after every death would be an
exhausting exercise and instead I wish to
consider here how a group sequential
approach could be used.
The usual group sequential testing
described in Sections 3 and 4 is at equally
spaced numbers of patients, whereas for
the log-rank test it would seem more
appropriate, and asymptotically equiva-
lent, to analyse at equally spaced numbers
of deaths. The theoretical details have not
been worked out yet but I believe that
the nominal significance levels in Table II
would provide an overall significance
level of 005 for a log-rank group sequen-
tial design. Further research would also
be needed to define power calculations in
this context.
Such an approach would mean that a
considerable time would elapse between
the start of the trial and the first analysis,
but the time intervals between analyses
would then shorten as more patients were
entered and deaths occured more freouent-
ly. In this way one would avoid any unduly
premature survival analyses based on
very few deaths.
The success of group sequential sur-
vival designs primarily depends on the
speed with which deaths are reported.
The consequences of an early significant
result may just be cessation of patient
entry, but if treatment is ongoing (e.g.
long-term chemotherapy) use of the in-
ferior treatment on patients already
entered may also cease, so that the whole
trial is closed. In this latter case, there
will be no further data to add to the
survival comparison, except as a result of
administrative delay, but in the former
case there will be greater difficulty of
statistical interpretation as further sur-
vival follow-up continues. This problem
of a stopping rule being followed by
further data has not been satisfactorily
resolved but the best approach may be
a conventional fixed-sample-size analysis
of the final data with some informal
acknowledgement that a stopping rule
has been used.
SECRECY OF INTERIM ANALYSES
Repeated presentation ofinterim results
can have considerable influence on the
participating investigators. An early in-
terim analysis showing treatment com-
parisons can have disastrous effects on the
future progress of a trial. If there is little
difference between treatments some in-
vestigators may lose interest. However, a
more serious situation arises if there are
interesting but non-significant differences.
Some participants may then drop out of
the trial arguing that they believe there
is a genuine difference, while others may
continue in a half-hearted manner with
perhaps an increased tendency to adapt
the supposedly inferior treatment, remove
patients from it prematurely or, worse still,
interfere with the randomization.
Investigators may not be happy with
complete secrecy, so a compromise solu-
tion may be required whereby results are
presentedforalltreatments, combinedwith
an additional statement that there is no
significant difference as yet. Some small
committee perhaps made up of one
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statistician and a non-participating clin-
ician could keep a detailed check on the
interim results which would only be
presented to others in full when treatment
differences are of sufficient magnitude to
merit termination of the trial.
An additional problem is the premature
publication of results while a trial is still
in progress, which has the more serious
effect that the whole medical community
may be prejudiced towards a particular
conclusion before the full results are
known. Such early public presentation
took place in at least 7 of the 40 survey
trials mentioned above.
CONCLUSIONS
(1)Formost clinicaltrialsin cancer, some
form of informal ongoing analysis of
results is undertaken, though conventional
sequential methods are hardly ever used.
(2) This practice of periodically analys-
ing the accumulating data can be formula-
ted more precisely as a group sequential
design, whereby stopping rules are based
on repeated significance testing at equal
intervals. There appears no great advan-
tage in carrying out many repeated tests,
both for statistical reasons and because of
the effort involved. One sensible design
would be to plan for no more than 10
repeated analyses, with a decision to stop
the trial if the main treatment difference
is significant at the I% level.
(3) Such statistical stopping rules can
never be rigorously applied but should
improve the objectivity of decision-
making.
(4) Difficulties in obtaining adequate
patient accrual, administrative ineffici-
ency and premature dissemination of
results are major faults in the organization
of many cancer trials for which no amount
of statistical refinement can correct.
I am grateful to Professor P. Armitage for helpful
advice.
REFERENCES
ARMIITAGE, P. (1975) Sequeniti(al Medical Trials.
Oxford: Blackwell.
MCPHERSON, K. (1974) Statistics: the problem of
examiniing accumulating clata more than once.
N. Engl. J. MIed., 290, 501.
MCPHERSON, K. (1977) Sequential analysis of
clinical trial data. In Clinical Tria(ls, Chapter 6,
Eds. F. N. and S. Johnson. Oxford: Blackwell.
PococK, S. J. (1977) Group sequential methods in
the design and analysis of clinical trials. Bio-
metritL, 64, 191.
PococK, S. J., ARMiITACGE, P. & GALTON, D. A. G.
(1978) The size of cancer clinical trials: an inter-
national survey. UICC Tech. Rep. Series, 36, 5.